Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Global Recombinant Proteins Market projected to be worth USD 2.4 billion by 2030.

According to SPER Market Research, the recombinant proteins market estimated to reach USD 2.4 billion by 2030 with a CAGR of 10.2%. The fuels for the escalation of the market are; the collaboration of industry and academia, expiring of patents of biologic product, growing investments from the government in the pharmaceutical and bio pharmaceutical research and development.

Impact of COVID-19 on the Recombinant Proteins Market

The outbreak of COVID-19 gave an upsurge to the Recombinant Proteins Market; this is due to increase in research and development to reach out the cause of the infection. Companies with product for COVID-19 have a positive expansion.

Scope of the report:

Market size available for years 2019-2030

Base year considered

2021

Forecast period

2022-2030

Segments covered

By Product, By Application, By End-User, By Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

Abcam plc, Abnova Corporation, ACRO Biosystems, Aviva Systems Biology Corporation, Biolegend, Bio-Rad Laboratories, Inc. , Biotech Corporation, BPS Bioscience, Inc., CellGenix GmbH, Enzo Life Sciences, Inc., GenScript, Icosagen AS, Merck KGaA, Miltenyi Biotech, Neuromics, PeproTech, Inc., ProSpec TechnoGene Ltd., Proteintech Group, Inc., ProteoGenix, R&D Systems, RayBiotech Inc, RICHCORE LIFESCIENCES PVT LTD, Sino Biological Inc., STEMCELL Technologies Inc, StressMarq Biosciences Inc, Thermo Fisher Scientific, Inc., United States Biological.

Drivers: increasing government funding and growing Research & Development costs in pharmaceutical & biotechnology companies

Government funding, growing pharmaceutical and biopharmaceuticals research and development are the key factors that drive the escalation of the market.

Restraints: declining price of recombinant Protein

Due to concentration of various market players in the production of recombinant Protein with no varying price; this lead to resist the escalation of the market.

Opportunity: Emerging Economies

Emerging Economies, like Asia Pacific is projected to tender huge opportunities for the players in this market; this is due to rising prevalence of infectious chronic disease, multiple healthcare sector, growing government funding in the research and development of the advanced techniques in proteomic and genomic research, increasing geriatric population, friendly regulatory policies.

Global Recombinant Proteins Market, By Product:

Based on the Product, Global Recombinant Proteins Market is segmented as; Adhesion Molecules and Receptors, Growth Factors and Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, Structural Proteins, Other Recombinant Proteins.

Global Recombinant Proteins Market, By Application:

Based on the Application, Global Recombinant Proteins Market is segmented as; Drug Discovery & Development (Biologics, Cell & Gene Therapy, Vaccines), Biopharmaceutical Production, Biotechnology Research, Academic Research Studies, Other Applications (diagnostics, forensic, and cosmetology applications).

Global Recombinant Proteins Market, By End-User:

Based on the End-User, Global Recombinant Proteins Market is segmented as; Academic Research Institutes, Biotechnology Companies, Contract Research Organizations, Pharmaceutical & Biopharmaceutical Companies, Other End Users [diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent diagnostic laboratories), forensic laboratories, and the cosmetic industry].

Global Recombinant Proteins Market, By Region:

North America owns the prime share of the market; and this is due to the presence of top market players, government funding, growing prevalence of infectious and chronic diseases, growing research and development.